transmembrane protein with EGF like and two follistatin like domains 2Genealiases: CT120.2 · HPP1 · TENB2 · TPEF · TR · TR-2
Q-omics provides the consensus-scored TMEFF2 profile across patient tissues and cancer cell-line models. TMEFF2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEFF2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TMEFF2 RNA expression shows 14,624 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where TMEFF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEFF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEFF2 survival associations across molecular data types. TMEFF2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEFF2 RNA expression–survival associations across cancer types. High TMEFF2 expression shows unfavorable associations in ACC, UCEC and LIHC, but favorable associations in LGG, KIRP and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEFF2 RNA expression.
This table summarizes TMEFF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEFF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEFF2 shows lower tumor expression in COAD, BLCA, THCA, HNSC, KICH and STAD. The COAD box plot shows higher TMEFF2 RNA expression in normal versus tumor tissue (log2 FC = −0.559, t-test p < 0.001).
This table shows molecular features associated with TMEFF2 in patient tissues and cancer cell lines. In patient samples, TMEFF2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEFF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
